Patritumab Deruxtecan: Paving the Way for EGFR-TKI–Resistant NSCLC

Sun Min Lim, Chang Gon Kim, Jii Bum Lee, Byoung Chul Cho

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


HER3 is ubiquitously expressed in EGFR-mutant non–small cell lung cancer (NSCLC) irrespective of resistant mechanisms to EGFR tyrosine kinase inhibitors, thus garnering attention as a valuable therapeutic target. In this issue of Cancer Discovery, Jänne and colleagues highlight early clinical data supporting patritumab deruxtecan as a potentially appreciable agent for previously treated EGFR-mutant NSCLC.

Original languageEnglish
Pages (from-to)16-19
Number of pages4
JournalCancer Discovery
Issue number1
Publication statusPublished - 2022 Jan

Bibliographical note

Funding Information:
B.C. Cho reports grants from Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, Ono, Dizal Pharma, MSD, AbbVie, Medpacto, GIInnovation, Eli Lilly, Blueprint medicines, Interpark Bio Convergence Corp.; personal fees from Novartis, AstraZeneca, Boehringer-Ingelheim, Roche, BMS, Ono, Yuhan, Pfizer, Eli Lilly, Janssen, Takeda, MSD, Janssen, Med-pacto, Blueprint Medicines, TheraCanVac Inc, Gencurix Inc, Bridge-bio Therapeutics, KANAPH Therapeutic Inc, Cyrus Therapeutics, Interpark Bio Convergence Corp., KANAPH Therapeutic Inc, Brigebio

Publisher Copyright:
© 2022 American Association for Cancer Research

All Science Journal Classification (ASJC) codes

  • Oncology


Dive into the research topics of 'Patritumab Deruxtecan: Paving the Way for EGFR-TKI–Resistant NSCLC'. Together they form a unique fingerprint.

Cite this